Mira Pharmaceuticals Inc MIRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
-
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
-
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
-
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
-
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
-
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
-
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
-
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- —
- Total Number of Employees
- 6
Valuation
|
Metric
|
MIRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.79 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MIRA
|
|---|---|
Quick Ratio | 3.54 |
Current Ratio | 3.68 |
Interest Coverage | −3.17 |
Quick Ratio
MIRA
Profitability
|
Metric
|
MIRA
|
|---|---|
Return on Assets (Normalized) | −203.52% |
Return on Equity (Normalized) | −262.65% |
Return on Invested Capital (Normalized) | −164.50% |
Return on Assets
MIRA
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Jqjqwdvslh | Qpr | $797.4 Bil | |||
| Johnson & Johnson
JNJ
| Kbdxytz | Chkn | $386.4 Bil | |||
| AbbVie Inc
ABBV
| Jzxshplyg | Gmjx | $345.2 Bil | |||
| Merck & Co Inc
MRK
| Lchwfyxh | Hgq | $279.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Mjyrwkqgmv | Tvm | $247.5 Bil | |||
| AstraZeneca PLC ADR
AZN
| Xdslvxgkm | Ryjxk | $245.8 Bil | |||
| Novartis AG ADR
NVS
| Cpgzqfqph | Zzbts | $232.2 Bil | |||
| Amgen Inc
AMGN
| Mchzxslkp | Vwt | $170.6 Bil | |||
| Pfizer Inc
PFE
| Ftvgnjw | Dnqnz | $160.6 Bil | |||
| Sanofi SA ADR
SNY
| Kplgghlh | Jfht | $141.7 Bil |
United States